Europe-based Kanabo Group Plc (LSE: KNB), the first medical cannabis company to IPO on London Stock Exchange, has signed a letter of intent to acquire Materia - a processor and distributor of medical cannabis and CBD products across Europe for an undisclosed amount. The merger would create the largest publicly traded cannabis company in the EU. According to management, Materia infrastructure supplements that of Kanabo, and will be crucial to expanding and strengthening the company’s existing supply value chain in the medical cannabis and CBD realms. “We are excited at the prospect of joining forces with Kanabo’s team. As the first medical cannabis company approved to list on the London Stock Exchange, Kanabo’s ambition to be a market leader matches our own and we believe that our combined infrastructure will generate significant value for our shareholders, partners, customers and patients,” Materia’sDeepak Anand told Benzinga. Pre-merger, Kanabo's valuation stands slightly below $100 million. With a focus on distributing cannabis-derived products for medical patients and non-THC products for CBD consumers, Kanabo has conducted extensive research & development in order to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers and various non-smoking consumption solutions. Encuentra nuestro contenido en Español en El Planteo: Cannabis Recreativo en Europa: Comienza la Cuenta Regresiva Final Curaleaf en Europa y EEUU, ¿Qué Depara el Futuro Para la Empresa de Cannabis? See more from Benzinga Click here for options trades from Benzinga Counter-Culture Icon Tommy Chong Explains Why He Embraces The Corporatization Of Cannabis The Week In Cannabis: Tilray's Huge Week, Colin Hanks, Allen Iverson, Seth Rogen And More © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Kanabo's Acquisition of Materia Will Create Europe's Largest Public Cannabis Company
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...